Repurposing Lopinavir: Systematic Identification of MERS-CoV Inhibitors via FDA-Approved Compound Screening

Study Background and Research Question

The 2012 emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) posed a significant global health challenge, marked by high case fatality rates (~30%) and rapid, unexplained increases in confirmed infections. Despite the urgency, no therapeutic agents had been registered for direct use against human coronaviruses, and the protracted pace of conventional antiviral drug development was insufficient to address acute outbreaks. Recognizing this translational gap, de Wilde et al. conducted a comprehensive screen of FDA-approved drugs to identify candidates with immediate potential for antiviral intervention against MERS-CoV (reference study).

Key Innovation from the Reference Study

The critical innovation in de Wilde et al.'s work lies in the rapid repurposing strategy: systematically evaluating an extensive library of 348 FDA-approved small molecules for anti-MERS-CoV activity in cell culture. By leveraging compounds with established clinical safety profiles, this approach sidesteps many early-phase development barriers and accelerates the timeline for translational antiviral research. Among the four molecules identified, Lopinavir (ABT-378)—a potent HIV protease inhibitor—demonstrated robust inhibition of MERS-CoV replication at low-micromolar concentrations. This not only reinforces the utility of drug repurposing in emerging infectious disease settings but also highlights the potential for crossover between antiviral drug classes.

Methods and Experimental Design Insights

The study's screening protocol employed Vero E6 cell cultures, a standard model for coronavirus infection research, to evaluate compound efficacy against MERS-CoV. Each of the 348 FDA-approved drugs was tested for its capacity to suppress viral replication. Selected hits were further validated via dose-response assays to determine their 50% effective concentrations (EC₅₀), providing a quantitative basis for comparing antiviral potency. Notably, Lopinavir was included based on its established role in HIV infection research and protease inhibition assays, offering mechanistic plausibility for cross-coronavirus activity.

Protocol Parameters

• Cell lines: Vero E6 cells used as the primary host for MERS-CoV infection studies.
• Drug screening concentration: Initial screens typically employed concentrations in the low-micromolar range, followed by EC₅₀ determination for active hits.
• Validation: Hits were confirmed by dose-response analysis, with Lopinavir showing EC₅₀ values between 3 and 8 μM for MERS-CoV inhibition (reference study).
• Comparative assays: The inhibitory activities of Lopinavir and other hits were also tested against SARS-CoV and human coronavirus 229E to assess spectrum of activity.
• Workflow suggestion: When adapting similar antiviral screens, ensure consistent cell density, virus inoculum, and control conditions to maintain reproducibility and robustness of EC₅₀ measurements.

Core Findings and Why They Matter

From the initial library, four compounds—chloroquine, chlorpromazine, loperamide, and Lopinavir—emerged as inhibitors of MERS-CoV replication, each exhibiting EC₅₀ values in the range of 3–8 μM. The identification of Lopinavir is particularly significant, as it is a highly potent, clinically utilized HIV protease inhibitor (ABT-378), and its antiviral activity spans both wild-type and mutant HIV strains. The cross-inhibition of coronaviruses by Lopinavir, including SARS-CoV and HCoV-229E, suggests a broader antiviral potential than previously recognized (reference study).

This finding provides a strong mechanistic rationale for exploring Lopinavir in the context of coronavirus outbreaks and supports the immediate evaluation of its efficacy in animal models and clinical settings. Importantly, while none of the compounds completely abolished viral replication, moderate reductions in viral load may still confer clinical benefit by enabling host immune responses to mount more effectively—a hypothesis that can be tested in follow-up translational studies.

Comparison with Existing Internal Articles

The reference study's systematic screening methodology and focus on drug repurposing are echoed in several recent literature analyses. For instance, "Repurposing Lopinavir: Inhibition of MERS-CoV in Cell Culture" emphasizes how the identification of Lopinavir through FDA-approved compound screens accelerates the search for antiviral agents during outbreaks. Similarly, "Lopinavir Identified as MERS-CoV Inhibitor via FDA Drug Screen" highlights the operational value of such screens for rapid candidate prioritization in emergent viral contexts. Beyond the antiviral focus, "Lopinavir (ABT-378): Precision HIV Protease Inhibition and Beyond" provides a mechanistic discussion of Lopinavir's established role in HIV protease inhibition assays, and its relevance as a research tool for resistance and potency studies. These resources reinforce the translational potential and technical rationale underscored by the de Wilde et al. findings.

Limitations and Transferability

While the identification of Lopinavir and related compounds as MERS-CoV inhibitors is promising, several limitations temper immediate translational conclusions. The reported antiviral activities are derived from cell culture models, which may not fully recapitulate in vivo pharmacokinetics, tissue distribution, or immunological interactions. The EC₅₀ values for Lopinavir are in the low-micromolar range for MERS-CoV, which is higher than its nanomolar potency against HIV protease in standard HIV protease inhibition assays. Moreover, the study did not evaluate synergistic or antagonistic effects between the identified hit compounds, nor did it address potential cytotoxicity at higher concentrations. Finally, while Lopinavir is orally bioavailable and extensively used in HIV research, its efficacy, safety, and optimal dosing parameters for coronavirus infections require rigorous preclinical and clinical validation.

Why this cross-domain matters, maturity, and limitations

The successful identification of an HIV protease inhibitor as an in vitro inhibitor of MERS-CoV highlights the value of cross-domain compound repurposing, especially in the face of rapidly emerging infectious diseases. This approach can dramatically shorten the timeline from discovery to clinical testing, leveraging known pharmacology and safety data. However, maturity of this strategy is limited by the need for in vivo validation, as well as careful consideration of virus-specific replication mechanisms and host-pathogen interactions. The translational bridge from HIV to coronavirus inhibition remains promising but incomplete without further preclinical and clinical research.

Research Support Resources

For laboratories seeking to reproduce or extend similar antiviral screening workflows, Lopinavir (ABT-378) (SKU A8204) is available as a research-grade compound. Its well-characterized properties—such as high potency against both wild-type and mutant HIV proteases, established pharmacokinetic profile, and compatibility with HIV protease inhibition assays—make it a robust tool for both HIV and emerging coronavirus research. Researchers can reference the product information for detailed handling and experimental guidance, and consult literature such as de Wilde et al. for protocol adaptation and translational context.